Project Detail
Interagency Autism Coordinating Committee (IACC) logo
Office of Autism Research Coordination (OARC) logo

Targeted pharmacologic interventions for autism  

This project will examine the efficacy and tolerability of atomoxetine for treatment of hyperactivity associated with autism in children and adolescents. An 8-week randomized clinical trial will be conducted, and patients that respond well to short-term treatment with atomoxetine will be followed for an additional 10 months. Genetic polymorphisms of the cytochrome P450 2D6 gene will also be analyzed to determine their relationship to response and tolerability to atomoxetine. This research addresses the need to find safer and more effective medical treatments for autism and is also unique in its plan to identify genetic predictors of response to drug treatment in autism. Project Status


Funder National Institutes of Health
Fiscal Year Funding $355,516.00
Project Number 5R01MH077600-03
Principal Investigator Posey, David
Received ARRA Funding? No
Strategic Plan Question Question 4: Which Treatments And Interventions Will Help? (Interventions)
Strategic Plan Objective Yellow dot: Objective has some degree of funding, but less than the recommended amount. 4LC. Conduct at least one study to evaluate the safety and effectiveness of medications commonly used in the treatment of co-occurring conditions or specific behavioral issues in people with ASD by 2015. IACC Recommended Budget: $10,000,000 over 5 years.
Federal or Private? Federal
Institution Indiana University-Purdue University Indianapolis
State/Country Indiana
Web Link 1 Targeted pharmacologic interventions for autism (External web link)
Web Link 2 No URL available.
Web Link 3 No URL available.
History/Related Projects Targeted pharmacologic interventions for autism | $370,481.00 | 2010 | 5R01MH077600-04
Targeted pharmacologic interventions for autism | $341,475.00 | 2008 | R01MH077600-02